Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
PRESS RELEASES
Y-mAbs Announces Sale Of Priority Review Voucher
By GlobeNewswire
Dec 28, 2020 9:00 AM EST
PRESS RELEASES
Y-mAbs Announces Pipeline Update
By GlobeNewswire
Dec 16, 2020 9:00 AM EST
PRESS RELEASES
Y-mAbs Announces Update On DANYELZA® (naxitamab-gqgk) At ESMO
By GlobeNewswire
Dec 9, 2020 9:00 AM EST
PRESS RELEASES
FDA Approves Y-mAbs' DANYELZA® (naxitamab-gqgk) For The Treatment Of Neuroblastoma
By GlobeNewswire
Nov 25, 2020 5:02 PM EST
PRESS RELEASES
Y-mAbs Announces Update On Omburtamab In DIPG
By GlobeNewswire
Nov 19, 2020 9:00 AM EST
PRESS RELEASES
Y-mAbs Announces FDA Clearance Of IND For Lutetium-177 Labeled Omburtamab Antibody For Adult Indications
By GlobeNewswire
Oct 26, 2020 9:10 AM EDT
PRESS RELEASES
Y-mAbs Announces Update On Naxitamab And Omburtamab In Neuroblastoma
By GlobeNewswire
Oct 16, 2020 9:00 AM EDT
PRESS RELEASES
Y-mAbs Announces FDA Clearance Of IND For Its Lutetium-177 Labeled Omburtamab Antibody
By GlobeNewswire
Oct 14, 2020 9:00 AM EDT
PRESS RELEASES
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Y-mAbs Therapeutics, Inc. - YMAB
By PR Newswire
Oct 8, 2020 6:13 PM EDT
PRESS RELEASES
Y-mAbs' Nivatrotamab For The Treatment Of Patients With Neuroblastoma Granted Orphan Drug Designation And Rare Pediatric Disease Designation By FDA
By GlobeNewswire
Oct 7, 2020 9:00 AM EDT
PRESS RELEASES
Y-mAbs Provides Regulatory Update On Omburtamab For The Treatment Of Patients With Neuroblastoma
By GlobeNewswire
Oct 5, 2020 4:01 PM EDT
PRESS RELEASES
Y-mAbs Announces Completion Of Submission Of Omburtamab Biologics License Application To FDA
By GlobeNewswire
Aug 6, 2020 9:00 AM EDT
PRESS RELEASES
Y-mAbs Announces Data To Be Presented At 2020 SIOP
By GlobeNewswire
Jul 27, 2020 4:01 PM EDT
PRESS RELEASES
Y-mAbs Announces Update On SADA Technology And New Preclinical SADA Construct
By GlobeNewswire
Jul 14, 2020 9:00 AM EDT
PRESS RELEASES
Y-mAbs Announces Initiation Of Submission Of Omburtamab Rolling Biologics License Application To The FDA
By GlobeNewswire
Jun 30, 2020 4:01 PM EDT
PRESS RELEASES
Y-mAbs Announces U.S. FDA Acceptance Of Biologics License Application For Danyelza™ (naxitamab) For The Treatment Of Neuroblastoma For Priority Review
By GlobeNewswire
Jun 2, 2020 9:00 AM EDT
PRESS RELEASES
Y-mAbs Announces Data To Be Presented At 2020 ASCO Annual Meeting
By GlobeNewswire
May 13, 2020 9:00 AM EDT
PRESS RELEASES
Y-mAbs Announces Appointment Of Laura J. Hamill To Its Board Of Directors
By GlobeNewswire
Apr 24, 2020 9:00 AM EDT
PRESS RELEASES
Y-mAbs Announces Submission Of Naxitamab Biologics License Application To U.S. FDA
By GlobeNewswire
Apr 1, 2020 9:00 AM EDT
PRESS RELEASES
Y-mAbs To Announce 2019 Financial And Operating Results On March 12, 2020
By GlobeNewswire
Mar 5, 2020 9:00 AM EST
PRESS RELEASES
Y-mAbs Announces Positive Pre-BLA Meeting With FDA For Omburtamab
By GlobeNewswire
Feb 26, 2020 4:01 PM EST